IBI302
Phase 2Small molecule
Innovent Biologics (Suzhou) Co. Ltd.IBI302 is one of 48 small molecule programs targeting Wet Age-Related Macular Degeneration. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
180 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Beovu
NovartisPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Lucentis
NovartisPhase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Glucophage
EMD SeronoPhase 3
Intravitreal Ranibizumab
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema1 trial
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 2·NCT06908876·150 enrolled
Neovascular AMD1 trial
Wet Age-Related Macular Degeneration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI302. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details